Latest Metered-dose inhaler Stories

[316 Pages Report] Drug Delivery Technology Market Report categorizes the Global Market by Metered Dose Inhalers, Auto Injectors, Transdermal Patches, Drug Eluting Stentscand Infusion Pumps Forecasting - 2017. (PRWEB) May 02, 2013 The "Drug Delivery Technology Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Global Forecasts To 2017,"...

Gecko Health Innovations will announce their first product, GeckoCap, at the 2013 International CES. GeckoCap is a new monitoring technology for pediatric asthma inhalers. Cambridge, MA (PRWEB) January 02, 2013 Gecko Health Innovations Inc., a healthcare mobile technology company, announced today that its patent pending new solution for pediatric asthma, GeckoCap™, will be unveiled at the 2013 International CES® in Las Vegas, from January 8-11, in booth #73409 at the Eureka Park...

REDWOOD CITY, Calif., Oct. 24, 2012 /PRNewswire/ -- Pearl Therapeutics Inc. today announced the completion of the Company's randomized, double-blind, dose-ranging Phase 2b trial of PT003, Pearl's lead investigational inhaled combination bronchodilator product for the treatment of patients with moderate-to-severe COPD. This study assessed five BID doses of PT003, in which formoterol fumarate (FF) was co-formulated with five descending doses of glycopyrrolate (GP) and administered...

But high prescription volume and cost mean everyone needs to know how to use these devices correctly, says DTB Healthcare professionals are as bad as patients when it comes to knowing how to use inhalers prescribed for asthma and other respiratory conditions correctly, says an editorial in Drug and Therapeutics Bulletin (DTB). They therefore can't be relied on to teach patients how to use these devices correctly, says DTB. But as 45 million prescriptions for respiratory inhalers were...

RIDGEFIELD, Conn., Sept. 18, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that COMBIVENT RESPIMAT is now available by prescription in the United States. COMBIVENT( )RESPIMAT is a unique, propellant-free inhaler that uses a slow-moving mist to deliver the same active ingredients as COMBIVENT Inhalation Aerosol, which is delivered in a metered dose inhaler (COMBIVENT MDI). COMBIVENT RESPIMAT is indicated for use in patients with chronic...

REDWOOD CITY, Calif., Sept. 13, 2012 /PRNewswire/ -- Pearl Therapeutics Inc. today announced the completion of a randomized, double-blind Phase 2b dose-ranging study in which six doses of the long-acting muscarinic antagonist (LAMA), glycopyrrolate (GP) ranging from 18 micrograms to 600 nanograms BID were delivered via metered-dose inhaler (GP MDI; PT001) to patients with moderate-to-severe COPD. In this study (NCT01566773) and the previously conducted dose-ranging GP MDI studies, a...

VIENNA, Sept. 3, 2012 /PRNewswire/ -- Elevation Pharmaceuticals, Inc. today presented positive efficacy and safety results from the GOLDEN-1 study - a Phase 2b study evaluating EP-101 in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) - at the annual meeting of the European Respiratory Society in Vienna, Austria. As previously announced, EP-101 demonstrated a rapid onset, dose-related, statistically significant improvement in lung function compared to...

Primatene® Mist Critical For Millions of Asthmatics Lacking Health Insurance; All Manufacturer's Net Profits from Sales of Primatene® Mist will be Donated to Charity WASHINGTON, July 18, 2012 /PRNewswire-USNewswire/ -- The makers of Primatene® Mist have launched a campaign to put the over-the-counter inhaler back on the market in the United States, after it was banned because it contains a small amount of chlorofluorocarbons (CFCs), leaving millions of asthmatics without an...

SEATTLE, July 17, 2012 /PRNewswire/ -- Asthmapolis, a Wisconsin-based company dedicated to advancements in asthma treatment, partnered with Synapse to develop breakthrough technologies for asthma treatment. Combining medication sensors, mobile applications, and analytics, the Asthmapolis sensor attaches to existing rescue inhalers to collect data such as when and where patients experience asthma conditions. Having recently received U.S. Food and Drug Administration clearance,...

MADISON, Wis., July 11, 2012 /PRNewswire-iReach/ -- Asthmapolis announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its asthma sensor system and associated software to healthcare providers and their patients. (Photo: http://photos.prnewswire.com/prnh/20120711/CG38057) "We are thrilled to have achieved this important milestone to support our mission of providing tools to help patients and their healthcare providers better...